Overview

Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to investigate the initial dose and dose adjustment range for paricalcitol injection in patients with chronic kidney disease on hemodialysis who have secondary hyperparathyroidism.
Phase:
Phase 2
Details
Lead Sponsor:
Abbott
Collaborator:
Abbott Japan Co.,Ltd
Treatments:
Calcitriol
Ergocalciferols
Maxacalcitol